Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 2
2020 1
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Circulating soluble CD163 as a potential biomarker of diabetes complications.
Siwan E, Parry SN, Williams KH, McGill MJ, Wu T, Wong J, Twigg SM, Min D. Siwan E, et al. J Diabetes Complications. 2023 Aug;37(8):108525. doi: 10.1016/j.jdiacomp.2023.108525. Epub 2023 Jun 5. J Diabetes Complications. 2023. PMID: 37301062
AIMS: To investigate whether soluble CD163 (sCD163) is altered in those with diabetes and various subtypes of complications and non-alcoholic fatty liver disease (NAFLD), and whether it can assess disease complications and severity in peo …
AIMS: To investigate whether soluble CD163 (sCD163) is altered in those with diabetes and various subtypes of complications and non- …
Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease.
Ban LA, Shackel NA, McLennan SV. Ban LA, et al. Int J Mol Sci. 2016 Mar 14;17(3):376. doi: 10.3390/ijms17030376. Int J Mol Sci. 2016. PMID: 26985892 Free PMC article. Review.
In recent years, the global burden of obesity and diabetes has seen a parallel rise in other metabolic complications, such as non-alcoholic fatty liver disease (NAFLD). This condition, once thought to be a benign accumulation of hepatic fat, is …
In recent years, the global burden of obesity and diabetes has seen a parallel rise in other metabolic complications, such as non- …
Regulation and bioactivity of the CCN family of genes and proteins in obesity and diabetes.
Twigg SM. Twigg SM. J Cell Commun Signal. 2018 Mar;12(1):359-368. doi: 10.1007/s12079-018-0458-2. Epub 2018 Feb 6. J Cell Commun Signal. 2018. PMID: 29411334 Free PMC article. Review.
Evidence for this is currently derived from their dysregulation in key metabolic pathological states in humans, animal and in vitro models, and also pre-clinical effects of their bioactivities. CCN2 is the best studied in this disease process and the other CCNs are yet to …
Evidence for this is currently derived from their dysregulation in key metabolic pathological states in humans, animal and in vitro models, …
Targeting CCN2 protects against progressive non-alcoholic steatohepatitis in a preclinical model induced by high-fat feeding and type 2 diabetes.
Ren J, Wang X, Parry SN, Yee C, Gorrell MD, McLennan SV, Twigg SM. Ren J, et al. J Cell Commun Signal. 2022 Sep;16(3):447-460. doi: 10.1007/s12079-022-00667-1. Epub 2022 Jan 17. J Cell Commun Signal. 2022. PMID: 35038159 Free PMC article.
Type 2 diabetes is an independent risk factor for non-alcoholic steatohepatitis (NASH) progression and its mediators have not been resolved. ...This in vivo study indicates that CCN2 is a molecular target in NASH with high fat diet and diabetes, and th …
Type 2 diabetes is an independent risk factor for non-alcoholic steatohepatitis (NASH) progression and its mediators ha …
The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis.
Sabag A, Barr L, Armour M, Armstrong A, Baker CJ, Twigg SM, Chang D, Hackett DA, Keating SE, George J, Johnson NA. Sabag A, et al. J Clin Endocrinol Metab. 2022 Feb 17;107(3):862-881. doi: 10.1210/clinem/dgab795. J Clin Endocrinol Metab. 2022. PMID: 34724062
CONTEXT: Non-alcoholic fatty liver disease, characterized by excess fat accumulation in the liver, is considered the hepatic manifestation of metabolic syndrome. ...OBJECTIVE: The aim of this systematic review was to determine the effect …
CONTEXT: Non-alcoholic fatty liver disease, characterized by excess fat accumulation in the liver, …
Differing clinical phenotype for higher alanine-aminotransferase (ALT) compared with high-risk NAFLD fibrosis score in type 2 diabetes mellitus.
Williams KH, Burns K, Twigg SM. Williams KH, et al. J Diabetes Complications. 2018 Mar;32(3):321-324. doi: 10.1016/j.jdiacomp.2017.12.010. Epub 2017 Dec 29. J Diabetes Complications. 2018. PMID: 29398327
AIMS: The impact of non-alcoholic fatty liver disease (NAFLD) presence and severity on the diabetes phenotype remains unclear. ...CONCLUSIONS: In type 2 diabetes, the clinical phenotype of those with higher ALT is dissimilar, sometimes inverse, …
AIMS: The impact of non-alcoholic fatty liver disease (NAFLD) presence and severity on the diabetes pheno …
Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1.
Hou W, Watson C, Cecconie T, Bolaki MN, Brady JJ, Lu Q, Gatto GJ Jr, Day TA. Hou W, et al. J Biol Chem. 2024 Jun;300(6):107353. doi: 10.1016/j.jbc.2024.107353. Epub 2024 May 7. J Biol Chem. 2024. PMID: 38723751 Free PMC article.
The data from these biochemical and functional assays suggest a mechanism by which the MTARC1 p.A165T variant abrogates enzyme function which may contribute to its protective effect in liver disease....
The data from these biochemical and functional assays suggest a mechanism by which the MTARC1 p.A165T variant abrogates enzyme function whic …
Effect of exercise on hepatic steatosis: Are benefits seen without dietary intervention? A systematic review and meta-analysis.
Baker CJ, Martinez-Huenchullan SF, D'Souza M, Xu Y, Li M, Bi Y, Johnson NA, Twigg SM. Baker CJ, et al. J Diabetes. 2021 Jan;13(1):63-77. doi: 10.1111/1753-0407.13086. Epub 2020 Aug 11. J Diabetes. 2021. PMID: 32667128
BACKGROUND: Interventions involving both exercise and dietary modification are effective in reducing steatosis in nonalcoholic fatty liver disease (NAFLD). However, exercise alone may reduce liver fat and is known to have other positive effects on heal …
BACKGROUND: Interventions involving both exercise and dietary modification are effective in reducing steatosis in nonalcoholic fatty